1. Бадокин В.В. Перспективы применения ингибиторов ФНО-α при псориазе и псориатическом артрите // Клин. фармакология и терапия. 2005. 14. (1). 76–79.
2. Бадокин В.В. Псориатический артрит (клиника, диагностика, лечение) // Науч.-практ. ревматология. 2006. 44. (2s). 65–77.
3. Бадокин В.В. Фактор некроза опухоли-альфа – основная мишень патогенетической терапии псориаза и псориатического артрита // Дерматология. 2006. (1). 27–31.
4. Бунчук Н.В., Бадокин В.В., Коротаева Т.В. Псориатический артрит // Ревматология: национальное руководство. М.: ГЭОТАР-МЕДИА, 2008. 355–366.
5. Коротаева Т.В. Результаты оценки эффективности и безопасности нового ингибитора фактора некроза опухоли α – голимумаба в лечении псориатического артрита // Науч.-практ. ревматология. 2012. (3, Прил. 3). 17–22.
6. Пат. 2487736 РФ. Способ лечения асептического некроза головки бедренной кости / А.Г. Шушарин, М.П. Половинка, В.В. Морозов. Опубл. 20.07.2013.
7. Шушарин А.Г., Половинка М.П., Прохоренко В.М. Оценка эффективности лечения асептического некроза головки бедренной кости // Сиб. науч. мед. журн. 2015. 35. (3). 53–58.
8. Стешенко И.Г., Калягин А.Н. Возможности терапии распространенного псориаза кожи и псориатического артрита с использованием блокатора ФНО-α (голимумаба) // Соврем. пробл. ревматологии. 2014. 6. (6). 57–61.
9. Antoni C., Krueger G.G., de Vlam K. et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial // Ann. Rheum. Dis. 2005. 64. (8). 1150–1157.
10. ARCO (Association Research Circulation Osseous): committee on terminology and classification // ARCO News. 1992. 4. 41–46.
11. Christophers E. Psoriasis – epidemiology and clinical spectrum // Clin. Exp. Dermatol. 2001. 26. (4). 314–320.
12. Fiocco U., Sfriso P., Oliviero F. et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers // Joint Bone Spine. 2013. 80. 165–170.
13. Fitzgerald O., Dougados M. Psoriatic arthritis: one or more diseases? // Best Pract. Res. Clin. Rheumatol. 2006. 20. (3). 435–450.
14. Gladman D.D., Antoni C., Mease P. et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome // Ann. Rheum. Dis. 2005. 64. (Suppl. 2). ii14–ii17.
15. Haroon M., Gallagher P., Heffernan E. et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease // J. Rheumatol. 2014. 41. (7). 1357–1365.
16. Helmick C.G., Lee-Han H., Hirsch S.C. et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys // Am. J. Prev. Med. 2014. 47. (1). 37–45.
17. Hussar D.A. New drugs: Golimumab, besifloxacin hydrochloride, and artemether / lumefantrine // J. Am. Pharm. Ass. 2009. 49. (4). 570–573.
18. Huynh D., Kavanaugh A. Psoriatic arthritis: current therapy and future directions // Expert Opin Pharmacother. 2013. 14. 1755–1764.
19. Ibrahim G., Waxman R., Helliwell P.S. The prevalence of psoriatic arthritis in people with psoriasis // Arthritis Rheum. 2009. 61. (10). 1373–1378.
20. Jamnitski A., Symmons D., Peters M.J. et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review // Ann. Rheum. Dis. 2013. 72. (2). 211–216.
21. Kane D., Stafford L., Bresnihan B. et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience // Rheumatology. 2003. 42. (12). 1460–1468.
22. Kavanaugh A., Antoni C.E., Gladman D. et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year // 2006. 65. (8). 1038–1043.
23. Kavanaugh A., McInnes I., Mease P. et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis twenty-four-week efficacy and safety results of a randomized, placebo-controlled study // Arthritis Rheum. 2009. 60. (4). 976–986.
24. Kavanaugh A., McInnes I.B., Mease P. et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) // Ann. Rheum. Dis. 2014. 73. (9). 1689–1694.
25. Lebwohl M. Psoriasis // Lancet. 2003. 361. (9364). 1197–1204.
26. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis // Nature. 2007. 445. (7130). 866–873.
27. Martínez-Ferrer M.A., Peris P., Guañabens N. Osteonecrosis. What is new? // Reumatol. Clin. 2007. 3. (2). 78–84.
28. Mease P.J., Kivitz A.J., Burch F.X. et al. Etanercept treatment of psoriatic arthritis – Safety, efficacy, and effect on disease progression // Arthritis Rheum. 2004. 50. (7). 2264–2272.
29. Mease P.J., Gladman D.D., Ritchlin C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis – Results of a double-blind, randomized, placebo-controlled trial // Arthritis Rheum. 2005. 52. (10). 3279–
3289.
30. Menter A., Gottlieb A., Feldman S.R. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics // J. Am. Acad. Dermatol. 2008. 58. (5). 826–850.
31. Meyer N., Paul C., Feneron D. et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients // J. Eur. Acad. Dermatol. Venereol. 2010. 24. (9). 1075–1082.
32. Mcdonough E., Ayearst R., Eder L. et al. Depression and anxiety in psoriatic disease: prevalence and associated factors // J. Rheumatol. 2014. 41. (5). 887–896.
33. McLaughlin M., Ostör A. Early treatment of psoriatic arthritis improves prognosis // Practitioner. 2014. 258. (1777). 21–24.
34. Minnock P., Kirwan J., Veale D. et al. Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis // Clin. Exp. Rheumatol. 2010. 28. (3). 401–404.
35. Myers W., Opeola M., Gottlieb A.B. Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis // Curr. Rheumatol. Rep. 2004. 6. (4). 306–313.
36. Nograles K.E., Davidovici B., Krueger J.G. New insights in the immunologic basis of psoriasis // Semin. Cutan. Med. Surg. 2010. 29. (1). 3–9.
37. Ogdie A., Schwartzman S., Eder L. et al. Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations // J. Rheumatol. 2014. 41. (11). 2315–2322.
38. Parisi R., Symmons D.P., Griffiths C.E. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence // J. Invest. Dermatol. 2013. 133. (2). 377–385.
39. Prinz J. The role of T cells in psoriasis // J. Eur. Acad. Dermatol. Venereol. 2003. 17. (3). 257–270.
40. Punzi L., Podswiadek M., Sfriso P. et al. Pathogenetic and clinical rationale for TNF-blocking therapy in psoriatic arthritis // Autoimmun. Rev. 2007. 6. 524–528.
41. Rapp S.R., Feldman S.R., Exum M.L. et al. Psoriasis causes as much disability as other major medical diseases // J. Am. Acad. Dermatol. 1999. 41. (3, Pt. 1). 401–407.
42. Raychaudhuri S.P., Wilken R., Sukhov A.C. et al. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies // J. Autoimmun. 2017. 76. 21–37.
43. Scarpa R., Atteno M., Lubrano E. et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study // Clin. Rheumatol. 2011. 30. 1063–1067.
44. Schön M.P., Boehncke W.H. Psoriasis // N. Engl. J. Med. 2005. 352. (18). 1899–1912.
45. Sukhov A., Adamopoulos I.E., Maverakis E. Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review // Clin. Rev. Allergy Immunol. 2016. 51. (1). 87–99.